FMR LLC

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Impresa Fund IV LLC

Disclosed balance after: 268

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Impresa Fund IV LLC

Disclosed balance after: 997,312

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 895

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VIII LP

Disclosed balance after: 0

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VIII LP

Disclosed balance after: 20,250

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-113013 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VIII LP

Disclosed balance after: 3,189,540

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0000950170-25-114526 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 1,107,547

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

F2 · ownership.nature: This amendment is being filed to correct the number of shares previously reported as being indirectly acquired by persons and entities whose shares are subject to reporting by the undersigned.

SEC source: 0000950170-25-101143 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Disclosed balance after: 2,073,665

SEC source: 0000950170-25-101141 · ownership.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,515,558

Underlying: Ordinary Shares · 78,930 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0000950170-25-016705 · ownership.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FIMM, LLC

Disclosed balance after: 0

Underlying: Ordinary Shares · 123 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0000950170-25-014244 · ownership.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VIII LP

Disclosed balance after: 0

Underlying: Common Stock · 3,120,934 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-25-014244 · ownership.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VIII LP

Disclosed balance after: 0

Underlying: Common Stock · 1,418,606 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-25-014244 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VIII LP

Disclosed balance after: 4,539,540

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-25-014244 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VIII LP

Disclosed balance after: 1,418,606

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On February 3, 2025, in connection with the completion of the issuer's initial public offering, each share of Series Seed Preferred Stock and Series A Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,541,511

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,542,511

F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,707,423

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000950170-25-004052 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 4,732,423

F1 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0000950170-24-107660 · ownership.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 392,085 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 712,430 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 10,818 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 1,115,333

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 723,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-107660 · ownership.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 10,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0000950170-24-032542 · ownership.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,541,868

Underlying: Ordinary Shares · 65,991 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 1,235,511

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $31.25 to $31.58. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 1,281,188

F1 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $30.25 to $31.25. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,771,913

SEC source: 0001209191-24-003394 · doc4.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,773,068

SEC source: 0001209191-24-003392 · doc4.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,563,865

Underlying: Ordinary Shares · 1,575 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-059756 · doc4.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 2,773,478

F1 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

SEC source: 0001209191-23-059755 · doc4.xml · derivative · entry 3

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Shares held by persons and entities whose shares are subject to reporting by the undersigned

Disclosed balance after: 1,564,390

Underlying: Ordinary Shares · 76,230 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-057698 · doc4.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 32,169

Underlying: Ordinary Shares · 48,258 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-057698 · doc4.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 2,733

Underlying: Ordinary Shares · 4,104 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $62.35 to $62.63. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice.

SEC source: 0001209191-23-056886 · doc4.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FMR Capital Inc.

Disclosed balance after: 391.495

F1 · date: On November 1, 2023, the Reporting Person's subscription to purchase Class S and Class D Common Shares of the Issuer was accepted. On November 29, 2023, the number of shares being purchased by the Reporting Person was fixed when the purchase price per share was determined by the Issuer.

SEC source: 0001209191-23-056886 · doc4.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FMR Capital Inc.

Disclosed balance after: 391.495

F1 · date: On November 1, 2023, the Reporting Person's subscription to purchase Class S and Class D Common Shares of the Issuer was accepted. On November 29, 2023, the number of shares being purchased by the Reporting Person was fixed when the purchase price per share was determined by the Issuer.

SEC source: 0001209191-23-053321 · doc4.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VI LP

Disclosed balance after: 48,255

Underlying: Ordinary Shares · 48,258 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

SEC source: 0001209191-23-053321 · doc4.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Advisors Fund VI LP

Disclosed balance after: 4,101

Underlying: Ordinary Shares · 4,104 shares

Expires not disclosed

F1 · derivative.exercise_price: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $65.52 to $65.70. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · derivative.exercise_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

F1 · derivative.expiration_date: Reported securities are American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. Any one American Depositary Share may be converted into three Ordinary Shares, and any three Ordinary Shares into one American Depositary Share, at any time at the election of the holder upon notice. Effective October 12, 2023, F-Prime Capital Partners Life Sciences Fund VI LP ("Fund VI") converted 193,023 ordinary shares to 64,341 ADSs and F-Prime Capital Partners Life Sciences Advisors Fund VI LP ("FPCPLSA") converted 16,407 ordinary shares to 5,469 ADSs. Fund VI sold 16,086 ADS and Advisors Fund VI sold 1,368 ADS. After the sale, Fund VI holds 48,255 and FPCPLSA holds 4,101 ADS as shown in Column 9.

SEC source: 0001209191-23-050240 · doc4.xml · derivative · entry 9

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FBRI LLC

Disclosed balance after: 0

Underlying: Common Stock · 88,289 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · derivative · entry 8

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 84,965 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · derivative · entry 7

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 0

Underlying: Common Stock · 3,475,646 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · derivative · entry 6

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 0

Underlying: Common Stock · 63,724 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · nonDerivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · FBRI LLC

Disclosed balance after: 88,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · nonDerivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Inc.

Disclosed balance after: 63,724

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 5,472,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-050240 · doc4.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Life Sciences Fund VII LP

Disclosed balance after: 5,387,375

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 12

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP

Disclosed balance after: 0

Underlying: Common Stock · 4,939 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 11

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · Impresa Fund III Limited Partnership

Disclosed balance after: 0

Underlying: Common Stock · 296,396 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 10

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 0

Underlying: Common Stock · 483,684 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

SEC source: 0001209191-23-043464 · doc4.xml · derivative · entry 9

FMR LLC · CIK 0000315066 · 10% owner · See Remark 1

10b5-1 filing: No plan indicated

Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP

Disclosed balance after: 0

Underlying: Common Stock · 150,809 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · price: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.exercise_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.

F1 · derivative.expiration_date: On July 25, 2023, in connection with the completion of the issuer's initial public offering, each share of Series B-1, B-2, C, and D Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.